ImmunityBio Gross Profit

The latest gross profit for IBRX is $160M as of June 2026. That compares with $52M in the prior-year period — up 201.0% year over year. That is below the Healthcare sector average of $67B. Investors often review this figure alongside ImmunityBio's historical trend and sector peers before judging valuation or financial health.

Over the past year, IBRX's gross profit moved from $52M to $160M — a 201.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ImmunityBio's operating scale or balance-sheet position.

Against Healthcare companies, IBRX currently prints $160M for gross profit, while the sector average sits near $67B. That is roughly 99.8% below the sector mean. Large gaps often invite a closer look at ImmunityBio's growth, margins, and balance sheet.

A gross profit figure of $160M for IBRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $67B. Explore the charts below for those layers of context.

After noting IBRX's gross profit ($160M), review year-over-year change from $52M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.